Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Inventory (2016 - 2025)

Integra Lifesciences Holdings' Inventory history spans 17 years, with the latest figure at $492.7 million for Q4 2025.

  • For Q4 2025, Inventory rose 14.83% year-over-year to $492.7 million; the TTM value through Dec 2025 reached $492.7 million, up 14.83%, while the annual FY2025 figure was $492.7 million, 14.83% up from the prior year.
  • Inventory for Q4 2025 was $492.7 million at Integra Lifesciences Holdings, up from $489.1 million in the prior quarter.
  • Across five years, Inventory topped out at $492.7 million in Q4 2025 and bottomed at $311.1 million in Q3 2022.
  • The 5-year median for Inventory is $360.3 million (2023), against an average of $381.3 million.
  • The largest annual shift saw Inventory fell 9.79% in 2021 before it increased 20.03% in 2023.
  • A 5-year view of Inventory shows it stood at $317.4 million in 2021, then rose by 2.27% to $324.6 million in 2022, then rose by 20.03% to $389.6 million in 2023, then grew by 10.13% to $429.1 million in 2024, then increased by 14.83% to $492.7 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Inventory are $492.7 million (Q4 2025), $489.1 million (Q3 2025), and $465.1 million (Q2 2025).